Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica

Non-Small Cell Lung Cancer – Recurrent, Advanced, or Metastatic

Initial criteria

age ≥ 18 years
EITHER tumor positive for EGFR exon 19 deletion or exon 21 L858R, ALK, RET, or ROS1 OR tumor negative for these biomarkers and meets one of the following:
first-line therapy for EGFR exon 20 mutation, NRG1 gene fusion, or ERBB2 (HER2) mutation positive
first-line or subsequent therapy for BRAF V600E, NTRK1/2/3 gene fusion, or MET exon 14 skipping mutation
subsequent therapy for EGFR S768I, L861Q, and/or G719X mutation positive
first-line or continuation maintenance therapy when tumor has no actionable mutations (none of EGFR exon 19 deletion, exon 21 L858R, EGFR S768I, L861Q, G719X, exon 20 insertion, ALK, ROS1, BRAF V600E, NTRK, METex14, RET, ERBB2, NRG1)
prescribed by or in consultation with an oncologist

1 year